WHO supports antibody treatment for high-risk COVID patients

A panel from the World Health Organization has approved the use of monoclonal antibodies for patients with COVID at the highest risk of hospitalization or for those who do not produce antibodies to fight the disease.

Developed by US drugmaker Regeneron and Swiss biotechnology company Roche, this treatment provides laboratory-made copies of antibodies that humans naturally produce when fighting infection. It has attracted attention as an alternative and expensive therapy for COVID-19, especially among some who have released a vaccine. A cocktail made of two infused antibodies, former President Donald J. Trump was treated for covid shortly after being diagnosed.

The Biden government has also advocated the use of the medication in countries where vaccination has stagnated and cases are rising, and its use is increasing in less vaccinated southern states.

The WHO panel cited data from three unpublished clinical studies as well as a large UK study of patients with Covid known as recovery, which showed that treatment tends to reduce the risk of hospitalization in patients who are mildly ill. which tends to be very bad because it is old, uninfected, or immune, for example. The data also show that treatment reduces the risk of death in patients with COVID who are admitted to a ventilator or hospital and who do not produce antibodies on their own.

Data from recovery studies show treatment can reduce deaths by 49 per 1,000 in critically ill patients and 49 per 1,000 in critically ill people, according to a press release Thursday.

The panel noted that low-risk patients and those with less severe symptoms were “unlikely to benefit from this antibody treatment” and urged these patients to view it as a “health mismatch and limited availability.” Avoid “no zoom”. medical. ”

On Friday, WHO asked Regeneron and Roche to reduce the cost of treatment and make it more affordable, especially in low- and middle-income countries. The WHO said it was in talks with Roche to donate doses to UNICEF, the United Nations children’s agency that makes the drug, for distribution in select areas.

In the US, some health professionals worry that funding the therapy, which the government is taking at $2,100 per dose, will cost more Americans time and money to vaccinate against Covid.

However, the Biden government is working to promote vaccination and therapy. Last month, dr. Marcela Nez-Smith said vaccination was the best way to prevent Covid-19, the White House Racial Health Advisor, and said the government was “ready to help states and territories and jurisdictions across the country, to add people”. “For the treatment of antibodies.